{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:18:41Z","timestamp":1772119121638,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,7,15]],"date-time":"2008-07-15T00:00:00Z","timestamp":1216080000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1007\/s00223-008-9152-3","type":"journal-article","created":{"date-parts":[[2008,7,14]],"date-time":"2008-07-14T13:57:12Z","timestamp":1216043832000},"page":"85-92","source":"Crossref","is-referenced-by-count":15,"title":["Parathyroid Hormone(1\u201384) Treatment of Postmenopausal Women with Low Bone Mass Receiving Hormone Replacement Therapy"],"prefix":"10.1007","volume":"83","author":[{"given":"I.","family":"Fogelman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. N.","family":"Fordham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. D.","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. D.","family":"Spector","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. A.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,7,15]]},"reference":[{"key":"9152_CR1","unstructured":"U.S. Department of Health and Human Services (2004) Bone health and osteoporosis: a report of the surgeon general. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General"},{"key":"9152_CR2","volume-title":"Physician\u2019s guide to prevention and treatment of osteoporosis","author":"National Osteoporosis Foundation","year":"2003","unstructured":"National Osteoporosis Foundation (2003) Physician\u2019s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington DC"},{"key":"9152_CR3","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","volume":"26","author":"AB Hodsman","year":"2005","unstructured":"Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688\u2013703","journal-title":"Endocr Rev"},{"key":"9152_CR4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S8756-3282(01)00613-5","volume":"29","author":"CJ Hernandez","year":"2001","unstructured":"Hernandez CJ, Beaupre GS, Marcus R, Carter DR (2001) A theoretical analysis of the contributions of remodeling space, mineralization, and bone balance to changes in bone mineral density during alendronate treatment. Bone 29:511\u2013516","journal-title":"Bone"},{"key":"9152_CR5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S8756-3282(01)00485-9","volume":"29","author":"P Roschger","year":"2001","unstructured":"Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K (2001) Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29:185\u2013191","journal-title":"Bone"},{"key":"9152_CR6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/edrv.23.1.0453","volume":"23","author":"R Marcus","year":"2002","unstructured":"Marcus R, Wong M, Heath H III, Stock JL (2002) Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 23:16\u201337","journal-title":"Endocr Rev"},{"key":"9152_CR7","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2265.1992.tb02323.x","volume":"37","author":"JN Bradbeer","year":"1992","unstructured":"Bradbeer JN, Arlot ME, Meunier PJ, Reeve J (1992) Treatment of osteoporosis with parathyroid peptide (hPTH 1\u201334) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin Endocrinol (Oxf) 37:282\u2013289","journal-title":"Clin Endocrinol (Oxf)"},{"key":"9152_CR8","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441","journal-title":"N Engl J Med"},{"key":"9152_CR9","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","volume":"146","author":"SL Greenspan","year":"2007","unstructured":"Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB (2007) Effect of recombinant human parathyroid hormone (1\u201384) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146:326\u2013339","journal-title":"Ann Intern Med"},{"key":"9152_CR10","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","volume":"349","author":"JS Finkelstein","year":"2003","unstructured":"Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216\u20131226","journal-title":"N Engl J Med"},{"key":"9152_CR11","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","volume":"349","author":"DM Black","year":"2003","unstructured":"Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207\u20131215","journal-title":"N Engl J Med"},{"key":"9152_CR12","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1359\/JBMR.050714","volume":"20","author":"C Deal","year":"2005","unstructured":"Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH (2005) Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 20:1905\u20131911","journal-title":"J Bone Miner Res"},{"key":"9152_CR13","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","volume":"350","author":"R Lindsay","year":"1997","unstructured":"Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F (1997) Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550\u2013555","journal-title":"Lancet"},{"key":"9152_CR14","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1359\/jbmr.2001.16.5.925","volume":"16","author":"F Cosman","year":"2001","unstructured":"Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R (2001) Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 16:925\u2013931","journal-title":"J Bone Miner Res"},{"key":"9152_CR15","unstructured":"European Agency for the Evaluation of Medicinal Products (2003) EMEA public statement on recent publications regarding hormone replacement therapy. http:\/\/www.emasonline.org\/content\/EMEA\/EMEA_3_12_2003.pdf"},{"key":"9152_CR16","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137\u20131148","journal-title":"J Bone Miner Res"},{"key":"9152_CR17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","volume":"19","author":"B Ettinger","year":"2004","unstructured":"Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745\u2013751","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"9152_CR18","first-page":"S113","volume":"21","author":"JA Gasser","year":"2006","unstructured":"Gasser JA, Ingold P, Venturiere A, Green JR (2006) Chronic subcutaneous, but not single intravenous dosing of rats with bisphosphonates results in reduced bone anabolic response to PTH. J Bone Miner Res 21(Suppl 1):S113","journal-title":"J Bone Miner Res"},{"key":"9152_CR19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3109\/13697139809085526","volume":"1","author":"D O\u2019Connell","year":"1998","unstructured":"O\u2019Connell D, Robertson J, Henry D, Gillespie W (1998) A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. II. An assessment of treatment effects. Climacteric 1:112\u2013123","journal-title":"Climacteric"},{"issue":"Suppl 2","key":"9152_CR20","first-page":"S85","volume":"17","author":"JP Bilezekian","year":"2006","unstructured":"Bilezekian JP, Greenspan SL, Black DM, Sellmeyer DE, Ensrud K, Rosen CJ, Fox J (2006) Concomitant administration of alendronate blunts the acute calcemic response to recombinant human parathyroid hormone 1\u201384: results from a PaTH substudy. Osteoporos Int 17(Suppl 2):S85","journal-title":"Osteoporos Int"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-008-9152-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-008-9152-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-008-9152-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T07:37:54Z","timestamp":1558683474000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-008-9152-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,15]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["9152"],"URL":"https:\/\/doi.org\/10.1007\/s00223-008-9152-3","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1123343.581334","asserted-by":"object"}]},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,15]]}}}